SCHEMBL3701552

SCHEMBL3701552

O=C(NCc1cccc(OC(F)(F)F)c1)c1nc2c(C(F)(F)F)cc(-c3ccco3)cn2c1Cl

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.45
PKM P14618 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ROCK2 O75116 4/20 0.44
ROCK1 Q13464 4/20 0.44
MAPK1 P28482 1/20 0.42
MAPK14 Q16539 1/20 0.42
GLS O94925 5/20 0.41
ATM Q13315 1/20 0.41
ADORA3 P0DMS8 2/20 0.40
ADORA2A P29274 2/20 0.40
ADORA2B P29275 2/20 0.40
ADORA1 P30542 2/20 0.40
RIPK1 Q13546 1/20 0.40
MMP13 P45452 1/20 0.38
NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3703954 0.92 ADORA3 (0.49) PKMRXFP1ROCK2ROCK1ADORA3
SCHEMBL3701613 0.92 PKM (0.44) PKMRXFP1MAPK1ADORA3ADORA2A
SCHEMBL3708699 0.89 PKM (0.47) PKMRXFP1MAPK1ADORA3ADORA2A
SCHEMBL3696233 0.89 PKM (0.49) PKMRXFP1MAPK1ATMADORA3
SCHEMBL3694815 0.86 ALDH1A1 (0.51) PKMRXFP1MAPK1ADORA3ADORA2A
SCHEMBL3702560 0.85 ADORA2A (0.46) PKMRXFP1MAPK1ADORA3ADORA2A
SCHEMBL7495068 0.85 PKM (0.46) PKMRXFP1MAPK1ADORA3ADORA2A
SCHEMBL3697615 0.85 HSD17B13 (0.44) PKMRXFP1ROCK2ROCK1MAPK1
SCHEMBL7490135 0.85 ALDH1A1 (0.51) PKMRXFP1MAPK1ADORA3ADORA2A
SCHEMBL7490205 0.85 RXFP1 (0.45) PKMRXFP1MAPK1ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 ABCB1 721/4885PKM 2286/4885RXFP1 4676/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 ABCB1 721/4885PKM 2286/4885RXFP1 4676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.